可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 臧益民,臧伟进,王晓明. 心力衰竭的病理生理机制及治疗概述[J]. 心脏杂志,2002,14(5):413-419.
[2] Sharon A,David W,Marshall H,et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult[J]. Circulation, 2001, 104:2996.
[3] Adams KF Jr. Pathophysiologic role of the renin angiotensin aldosterone and sympathetic nervous systems in heart failure[J]. Am J Health Syst Pharm,2004,61 (Suppl 2):S4-S13.
[4] Nancy J, Brown MD. Eplerenone cardiovascular protection[J]. Circulation, 2003, 107: 2512-2518.
[5] Moore TD, Nawarskas JJ, Anderson JR. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure[J]. Heart Dis, 2003, 5(5):354-363.
[6] Stier CT Jr, Koenig S, Lee DY, et al. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra)[J]. Heart Dis, 2003, 5(2):102-118.
[7] Khan NU, Movahed A. The role of aldosterone and aldosterone receptor antagonists in heart failure[J]. Rev Cardiovasc Med, 2004,5(2):71-81.
[8] Struthers AD, MacDonald TM. Review of aldosterone and angiotensin IIinduced target organ damage and prevention[J]. Cardiovasc Res,2004,61(4):663-670.
[9] Pitt B, Remme W, Zannad F, et al. Eplerenone postacute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction[J]. N Engl J Med, 2003,348(14):13091321.